Jun 2026 (Q2 FY26) — Aug 4, 2026
DaVita Q2 FY26 — Volume Growth Accelerates, Middle Molecule Clearance Expanded
Read the full callDaVita (DVA) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
DaVita earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 3,554 | +5.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 16.3 | +0.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 265 | +33.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$189.16 +4.68% · +$8.46
Performance +49.4% 1Y
1Y: $126.62 on 14 Oct 2025 → $189.16. High $240.96 (29 Jul 2026), low $103.87 (14 Jan 2026).
- Previous close
- $180.7
- 52-week range
- $103.87 – $240.96
- One year
- +50.13%
Overview
- Symbol
- DVA
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 5, 2026
DaVita Q1 FY26 — Strong Start with Raised Guidance and Volume Growth
Read the full callEvery analysed call
DaVita earnings calls (DVA)
Financials
What the filings say
Net profit, year on year: +33% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3,264 | 3,295 | 3,224 | 3,380 | 3,420 | 3,620 | 3,416 | 3,554 |
| Expenses | 2,729 | 2,729 | 2,785 | 2,842 | 2,914 | 3,059 | 2,934 | 2,975 |
| Operating profit | 535 | 565 | 439 | 538 | 506 | 561 | 482 | 579 |
| Operating margin | 16.4% | 17.2% | 13.6% | 15.9% | 14.8% | 15.5% | 14.1% | 16.3% |
| Profit before tax | 373 | 414 | 286 | 369 | 309 | 383 | 341 | 435 |
| Tax rate | 20.8% | 15.6% | 18.9% | 25.4% | 22.2% | 20.1% | 19.4% | 21.1% |
| Net profit | 215 | 259 | 163 | 199 | 150 | 234 | 198 | 265 |
| EPS ($ per share) | 2.56 | — | 2.05 | 2.62 | 2.09 | — | 2.93 | 4.10 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 2,743 | 1,432 | 853 | 354 | 174 | 598 | 1,535 | -328 |
| Total liabilities | 14,077 | 13,812 | 14,092 | 14,751 | 14,703 | 14,150 | 15,194 | 16,322 |
| Fixed assets | 3,394 | 3,473 | 3,522 | 3,480 | 3,256 | 3,074 | 2,941 | 2,813 |
| Investments | 3 | 12 | 20 | 22 | 78 | 12 | 51 | 24 |
| Total assets | 19,110 | 17,311 | 16,989 | 17,121 | 16,928 | 16,894 | 17,285 | 17,480 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1,772 | 2,072 | 1,979 | 1,931 | 1,565 | 2,059 | 2,022 | 1,887 |
| Cash from investing | -1,006 | 2,995 | -825 | -785 | -630 | -772 | -771 | -655 |
| Cash from financing | -625 | -4,696 | -1,847 | -1,083 | -1,121 | -1,170 | -817 | -1,375 |
| Net cash flow | 137 | 369 | -707 | 53 | -216 | 126 | 415 | -122 |
| Capital expenditure | -987 | -767 | -675 | -641 | -603 | -568 | -555 | -576 |
| Free cash flow | 785 | 1,306 | 1,304 | 1,289 | 961 | 1,491 | 1,467 | 1,311 |
DVA revenue by segment
| Segment | Q2 FY2024 | Q3 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| U S Dialysis With Intersegment | — | — | — | 86% | 87% | — | 86% | 85% | +3.4% |
| Other Operating Segments With Intersegment | — | — | 9% | 9% | 10% | 10% | 10% | 10% | +17.8% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Insider filings
85 filings between Oct 27, 2025 and Sep 22, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$508.68M
13 sales by 6 insiders
Compensation
not trading decisions- 44
- Award — granted as compensation
- 4
- Option exercise — converted options into shares
- 19
- Tax withheld — shares kept back by the company to cover tax
Also filed: 4 dispositions to the issuer, 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| BERKSHIRE HATHAWAY INC | — | $473.67M | Jul 31, 2026 |
| Rodriguez Javier | — | $14.53M | Jun 16, 2026 |
| ACKERMAN JOEL | — | $9.89M | May 7, 2026 |
| Maughan David Paul | — | $4.09M | May 12, 2026 |
| HEARTY JAMES O | — | $3.29M | May 15, 2026 |
| Waters Kathleen Alyce | — | $3.21M | Jun 15, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 22, 2026 | Maughan David Paul Chief Operating Officer, DKC | Tax withheld | 7,501 | $1.37M |
| Aug 15, 2026 | Arway Pamela M Director | Award | 278 | $0 |
| Aug 15, 2026 | Hollar Jason M. Director | Award | 278 | $0 |
| Aug 15, 2026 | YALE PHYLLIS R Director | Award | 278 | $0 |
| Aug 15, 2026 | Schoppert Wendy Lee Director | Award | 278 | $0 |
| Aug 15, 2026 | DESOER BARBARA J Director | Award | 278 | $0 |
| Aug 15, 2026 | Schechter Adam H Director | Award | 278 | $0 |
| Aug 15, 2026 | Pullin Dennis W Director | Award | 278 | $0 |
| Aug 15, 2026 | Moore Gregory J. Director | Award | 278 | $0 |
| Jul 31, 2026 | BERKSHIRE HATHAWAY INC 10% owner | Sale | 182,980 | $36.51M |
| Jun 16, 2026 | Rodriguez Javier Chief Executive Officer | Sale | 39,407 | $8.25M |
| Jun 15, 2026 | Waters Kathleen Alyce Chief Legal & Pub. Affairs Off | Sale | 8,950 | $1.86M |
| Jun 15, 2026 | Rodriguez Javier Chief Executive Officer | Sale | 30,000 | $6.29M |
| Jun 15, 2026 | Waters Kathleen Alyce Chief Legal & Pub. Affairs Off | Sale | 6,455 | $1.35M |
| May 26, 2026 | YALE PHYLLIS R Director | Gift | 5,038 | $0 |
| May 15, 2026 | Moore Gregory J. Director | Award | 250 | $0 |
| May 15, 2026 | Schoppert Wendy Lee Director | Award | 250 | $0 |
| May 15, 2026 | DESOER BARBARA J Director | Award | 250 | $0 |
| May 15, 2026 | Schechter Adam H Director | Award | 250 | $0 |
| May 15, 2026 | Hollar Jason M. Director | Award | 250 | $0 |
| May 15, 2026 | HEARTY JAMES O Chief Compliance Officer | Sale | 15,000 | $2.91M |
| May 15, 2026 | Arway Pamela M Director | Award | 250 | $0 |
| May 15, 2026 | YALE PHYLLIS R Director | Award | 250 | $0 |
| May 15, 2026 | Pullin Dennis W Director | Award | 250 | $0 |
| May 14, 2026 | HEARTY JAMES O Chief Compliance Officer | Disposition to issuer | 3,231 | $640.1K |
| May 14, 2026 | HEARTY JAMES O Chief Compliance Officer | Option exercise | 5,784 | $639.9K |
| May 14, 2026 | HEARTY JAMES O Chief Compliance Officer | Tax withheld | 1,117 | $221.3K |
| May 12, 2026 | Maughan David Paul Chief Operating Officer, DKC | Sale | 13,456 | $2.68M |
| May 11, 2026 | Maughan David Paul Chief Operating Officer, DKC | Sale | 7,073 | $1.41M |
| May 7, 2026 | ACKERMAN JOEL CFO and Treasurer | Sale | 51,471 | $9.89M |
| May 6, 2026 | HEARTY JAMES O Chief Compliance Officer | Sale | 2,184 | $381.9K |
| May 1, 2026 | BERKSHIRE HATHAWAY INC 10% owner | Sale | 1,220,376 | $182.86M |
| Mar 15, 2026 | Hollar Jason M. Director | Award | 332 | $0 |
| Mar 15, 2026 | BERRY CHRISTOPHER MICHAEL Chief Accounting Officer | Award | 3,649 | $0 |
| Mar 15, 2026 | ACKERMAN JOEL CFO and Treasurer | Tax withheld | 5,765 | $868.9K |
| Mar 15, 2026 | ACKERMAN JOEL CFO and Treasurer | Tax withheld | 3,362 | $506.7K |
| Mar 15, 2026 | ACKERMAN JOEL CFO and Treasurer | Award | 5,706 | $0 |
| Mar 15, 2026 | Schechter Adam H Director | Award | 332 | $0 |
| Mar 15, 2026 | Moore Gregory J. Director | Award | 332 | $0 |
| Mar 15, 2026 | Waters Kathleen Alyce Chief Legal & Pub. Affairs Off | Tax withheld | 4,348 | $655.3K |
| Mar 15, 2026 | Waters Kathleen Alyce Chief Legal & Pub. Affairs Off | Tax withheld | 940 | $141.7K |
| Mar 15, 2026 | Waters Kathleen Alyce Chief Legal & Pub. Affairs Off | Tax withheld | 26,118 | $3.94M |
| Mar 15, 2026 | Waters Kathleen Alyce Chief Legal & Pub. Affairs Off | Tax withheld | 2,457 | $370.3K |
| Mar 15, 2026 | Waters Kathleen Alyce Chief Legal & Pub. Affairs Off | Award | 3,185 | $0 |
| Mar 15, 2026 | HEARTY JAMES O Chief Compliance Officer | Tax withheld | 1,525 | $229.8K |
| Mar 15, 2026 | ACKERMAN JOEL CFO and Treasurer | Tax withheld | 33,693 | $5.08M |
| Mar 15, 2026 | HEARTY JAMES O Chief Compliance Officer | Tax withheld | 300 | $45.2K |
| Mar 15, 2026 | HEARTY JAMES O Chief Compliance Officer | Tax withheld | 8,984 | $1.35M |
| Mar 15, 2026 | HEARTY JAMES O Chief Compliance Officer | Tax withheld | 769 | $115.9K |
| Mar 15, 2026 | HEARTY JAMES O Chief Compliance Officer | Award | 1,128 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for DAVITA INC.
Free account. Everything above stays public.
Write why you follow DAVITA INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading